Browse studies

Find your next paid study

26,715 recruiting studies available now

I Can Join the Fight Against Cancer: An Intervention to Programmatically Build Grassroots Actions to Reduce the Cancer Burden

This clinical trial evaluates a community health education intervention (I CAN) for increasing community-driven actions to reduce the cancer burden in Western …

Healthy

Estimated

~$10 – $7,500

Roswell Park Cancer InstituteNCT06681077

MAgnetic Resonance Imaging or Computed Tomography Guided Stereotactic Body Radiotherapy With Online Adaptive Technology for Minimizing Toxicity During Salvage or AdjUvaNt Radiotherapy for ProstatE Cancer (MASAMUNE)

Single-arm, prospective registry study assessing changes in acute patient-reported urinary (GU) and gastrointestinal (GI) quality of life at the 24-month post-…

Prostate Cancer (CRPC)

Estimated

~$10 – $750

Jonsson Comprehensive Cancer CenterNCT07077239

Phase 2

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Background: High-grade neuroendocrine carcinomas (HGNEC) are cancers that develop in different parts of the body, including the digestive tract, genitals, nec…

Carcinoma, NeuroendocrineTumor, NeuroendocrineTumors, Neuroendocrine+2 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06406465

Phase 2

A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis

The main purpose of this study is to evaluate the effect and safety of efgartigimod PH20 SC compared to placebo in adults with systemic sclerosis. The study co…

Systemic Sclerosis (SSc)

A Phase 2 Open-label Study to Evaluate the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least One Treatment (VAY2EXPLORE)

The purpose of this study is to investigate the tolerability of ianalumab (9 mg/kg) with investigator's choice thrombopoietin receptor agonist (IC TPO-RA) in p…

Primary Immune Thrombocytopenia (ITP)Primary Evans Syndrome (ES)

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07421167

Observational

An Adaptive Design for Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial

The purpose of this study is to assess the best time to deliver a message to increase physical activity and how often participants will experience a pain episo…

Breast CancerCervical CancerBladder Cancer+4 more

Estimated

~$10 – $6,250

Medical College of WisconsinNCT07227077

Observational

Alveolar Ridge Preservation (ARP) in the Posterior Maxilla: A Clinical and Economic Evaluation of ARP After the Extraction of Maxillary Molars

Dental implants are a fixed replacement solution with reported long-term survival rates between 94-98% over 20-40 years. In order to ensure successful implant …

Alveolar Bone Loss

Estimated

~$10 – $6,250

Virginia Commonwealth UniversityNCT07433322

Phase 3

A Randomized, Triple-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Intravenous AMBTX-01 (Neridronate) for Treatment of Complex Regional Pain Syndrome Type 1 (CRPS-RISE)

Phase 3 Trial of AMBTX-01 (neridronate) for Complex Regional Pain Syndrome Type 1

Complex Regional Pain Syndrome Type I

Estimated

~$10 – $8,750

Ambros Therapeutics, Inc.NCT07210515

Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)

The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept wo…

Myelodysplastic Syndromes

Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)

The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin…

Biliary Tract Cancer

Estimated

~$10 – $7,500

AstraZenecaNCT07221253

Observational

Collection of Uterine Lavage in High-Risk Patients as a Potential Biomarker for Ovarian Cancer Risk

This clinical trial develops a non-surgical approach using uterine lavage samples to screen for progression to ovarian cancer in high-risk patients carrying BR…

BRCA Hereditary Ovarian CarcinomaFallopian Tube High Grade Serous AdenocarcinomaOvarian High Grade Serous Adenocarcinoma+1 more

Estimated

~$10 – $6,250

University of WashingtonNCT07772869

Investigation of the Natural Progression of Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance.

Background: Clonal Hematopoiesis of Indeterminate Potential (CHIP) is a change in a person s DNA that can increase a person s risk of developing blood cancers…

Clonal Hematopoiesis of Indeterminate PotentialClonal Cytopenia of Undetermined Significance

Estimated

~$10 – $675

National Heart, Lung, and Blood Institute (NHLBI)NCT04102423